Sign In
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- US Share Prices
- Stock Tips
- Share Chat
- FX
- News & RNS
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Faron Pharmaceuticals Share News (FARN)
FARN Share
Price
FARN Share
News
FARN Share
Chat
FARN Share
Trades3
FARN
Live RNS
FARN Share
Charts
FARN Level 2
Console
FARN Live
Share Price
FARN Broker
Ratings
FARN Directors
Deals
FARN Financial
Diary
FARN
Fundamentals
FARN Short
Positions
FARN
Media
FARN Company
Research
FARN Company
Timeline
Share Price Information for Faron Pharmaceuticals (FARN)
Last checked at -
Last checked at 
Intraday Faron Pharmaceuticals Share Chart
Faron Pharmaceuticals Notes Study Supporting Clevegen Programme
LONDON (Alliance News) - Faron Pharmaceuticals Oy on Monday said an article published in the Journal of Immunology has outlined the functional role of the company's Clever-1 treatment, part of its Clevegen cancer immunotherapy antibody programme.
Faron, which floated in London earlier this month, said the data published in the study supported Clever-1 as an immuosuppresive molecule and supports the use of Clevegen as an immunotherapy product.
"We are working hard to advance our Clevegen programme, as announced recently, towards clinical use as a new onco-immunological alternative," said Faron Chief Executive Markku Jalkanen.
Shares in Faron were trading flat at 275.00 pence on Monday.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Latest FARN News
- Faron Pharmaceuticals "Encouraged" After Latest Matins Trial Findings
5 Mar 2020 - Faron Pharmaceuticals Buys Rights For AOC3 Antagonist Platform
2 Mar 2020 - Faron Pharmaceuticals acquires rights to AOC3 inhibitors
2 Mar 2020 - Faron Pharmaceuticals Alters Traumakine Study After US FDA Feedback
6 Feb 2020 - Faron Pharma To Test Clevegen In Patients With Ovarian Cancer
27 Jan 2020 - Faron Pharma Gets Approval For Part II Trial Of Clevegen Drug
13 Jan 2020 - Faron Pharma requests arbitration over Traumakine manufacturing deal
30 Dec 2019 - Faron Pharma Files For Arbitration Amid Traumakine Deal Termination
30 Dec 2019
Related News
IN BRIEF: Faron Pharmaceuticals fined EUR30,000 by Nasdaq Helsinki
Faron Pharmaceuticals Ltd - Turku, Finland-based cancer drug developer - Says the Disciplinary Committee of Nasdaq Helsinki Ltd has imposed an EUR30,0...
WINNERS & LOSERS: James Cropper sees earnings up; Block sells stake
(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Tuesday.
Faron Pharmaceuticals News
Faron Pharmaceuticals "Encouraged" After Latest Matins Trial Findings
Faron Pharmaceuticals "Encouraged" After Latest Matins Trial Findings
Faron Pharmaceuticals Buys Rights For AOC3 Antagonist Platform
Faron Pharmaceuticals Buys Rights For AOC3 Antagonist Platform
Faron Pharmaceuticals acquires rights to AOC3 inhibitors
(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals has acquired rights for the potential new use of AOC3 inhibitors cov...
Faron Pharmaceuticals Alters Traumakine Study After US FDA Feedback
Faron Pharmaceuticals Alters Traumakine Study After US FDA Feedback
Faron Pharma To Test Clevegen In Patients With Ovarian Cancer
Faron Pharma To Test Clevegen In Patients With Ovarian Cancer
Faron Pharma Gets Approval For Part II Trial Of Clevegen Drug
Faron Pharma Gets Approval For Part II Trial Of Clevegen Drug
Faron Pharma requests arbitration over Traumakine manufacturing deal
(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced on Monday that, further to the update on 'Traumakine' drug...
Faron Pharma Files For Arbitration Amid Traumakine Deal Termination
Faron Pharma Files For Arbitration Amid Traumakine Deal Termination
Follow the stocks
